A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma

被引：0
|
作者：
Soushi Ibata
Tsutomu Sato
Hiroyuki Kuroda
Yasuhiro Nagamachi
Satoshi Iyama
Akihito Fujimi
Yusuke Kamihara
Yuichi Konuma
Masahiro Yoshida
Ayumi Tatekoshi
Akari Hashimoto
Hiroto Horiguchi
Kaoru Ono
Kazuyuki Murase
Kohichi Takada
Koji Miyanishi
Masayoshi Kobune
Yasuo Hirayama
Junji Kato
机构：
[1] Sapporo Medical University School of Medicine,Department of Medical Oncology and Hematology
[2] Steel Memorial Muroran Hospital,Gastroenterology and Hematology/Clinical Oncology, Internal Medicine
[3] Kiyota Hospital,Department of Hematology
[4] Oji General Hospital,Department of Hematology and Oncology
[5] Asahikawa Red Cross Hospital,Department of Hematology and Oncology
[6] Higashi Sapporo Hospital,Division of Internal Medicine
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Multiple myeloma; Consolidation/maintenance; Bortezomib; Lenalidomide; Dexamethasone; VRD;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1041 / 1049
页数：8
相关论文
共 50 条
  • [31] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Mori, Yasuo
    Choi, Ilseung
    Yoshimoto, Goichi
    Muta, Tsuyoshi
    Yamasaki, Satoshi
    Tanimoto, Kazuki
    Kamimura, Tomohiko
    Iwasaki, Hiromi
    Ogawa, Ryosuke
    Akashi, Koichi
    Miyamoto, Toshihiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 673 - 680
  • [32] A Phase I/II Trial Of Pomalidomide, Bortezomib and Dexamethasone In Patients With Relpased Or Refractory Multiple Myeloma
    Mikhael, Joseph R.
    Roy, Vivek
    Richardson, Paul G.
    Jakubowiak, Andrzej
    Laumann, Kristina
    LaPlant, Betsy R.
    Dispenzieri, Angela
    Rajkumar, S. Vincent
    Fonseca, Rafael
    Leung, Nelson
    Buadi, Francis
    Bergsagel, Leif
    Kyle, Robert
    Witzig, Thomas E.
    Reeder, Craig
    Lust, John A.
    Russell, Stephen
    Hayman, Suzanne R.
    Kumar, Shaji K.
    Dingli, David
    Ansell, Stephen M.
    Dalton, Robert
    Lin, Yi
    Sher, Taimur
    Kapoor, Prashant
    McCurdy, Arleigh
    Chanan-Khan, Asher
    Stewart, A. Keith
    Gertz, Morie A.
    Lacy, Martha Q.
    BLOOD, 2013, 122 (21)
  • [33] Bortezomib and Dexamethasone as Maintenance therapy in Relapse/Refractory multiple myeloma Patients.
    Benevolo, Giulia
    Larocca, Alessandra
    Pregno, Patrizia
    Gay, Francesca
    Botto, Barbara
    Orsucci, Lorella
    Evangelista, Andrea
    Palumbo, Antonio
    Vitolo, Umberto
    Boccadoro, Mario
    BLOOD, 2008, 112 (11) : 956 - 956
  • [34] Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Over 75 Years Old with Alternating Bortezomib/dexamethasone and Lenalidomide/dexamethasone: the MARBLE Trial
    Yokoyama, Akihiro
    Kada, Akiko
    Saito, Akiko M.
    Sawamura, Morio
    Komeno, Takuya
    Sunami, Kazutaka
    Takezako, Naoki
    ACTA MEDICA OKAYAMA, 2019, 73 (06) : 547 - 552
  • [35] Randomised, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone Followed by Ciltacabtagene Autoleucel Versus Bortezomib, Lenalidomide and Dexamethasone Followed by Lenalidomide and Dexamethasone Maintenance in Patients With Newly Diagnosed Multiple Myeloma Not Intended for Transplant: CARTITUDE-5
    Dytfeld, Dominik
    Dhakal, Binod
    Agha, Mounzer
    Manier, Salomon
    Delforge, Michel
    Kuppens, Steven
    Afifi, Salma
    Deraedt, William
    Taraseviciute-Morris, Agne
    Schecter, Jordan M.
    Gilbert, Jane
    Yalniz, Fevzi
    Florendo, Erika
    Pacaud, Lida
    Hungria, Vania
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 122 - 123
  • [36] Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
    Kristian T. Andersen
    Maja Hinge
    Agoston Gyula Szabo
    Erik Segel
    Tina Ormstrup
    Paw C. Holdgaard
    Niels Pallisgaard
    Gitte Kerndrup
    Torben Plesner
    Clinical Hematology International, 2020, 2 (1) : 35 - 39
  • [37] Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial
    Einsele, Hermann
    Engelhardt, Monika
    Tapprich, Christoph
    Mueller, Juergen
    Liebisch, Peter
    Langer, Christian
    Kropff, Martin
    Muegge, Lars O.
    Jung, Wolfram
    Wolf, Hans-Heinrich
    Metzner, Bernd
    Hart, Christina
    Gramatzki, Martin
    Hertenstein, Bernd
    Pfreundschuh, Michael
    Roesler, Wolf
    Fischer, Thomas
    Maschmeyer, Georg
    Kanz, Lothar
    Hess, Georg
    Jaeger, Elke
    Bentz, Martin
    Duerk, Heinz A.
    Salwender, Hans
    Hebart, Holger
    Straka, Christian
    Knop, Stefan
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (04) : 586 - 597
  • [38] PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB
    Mian, M.
    Pescosta, N.
    Luminari, S.
    Badiali, S.
    Marcheselli, L.
    Patriarca, F.
    Zambello, R.
    Mondello, P.
    Pascarella, A.
    Pitini, V.
    Cortelazzo, S.
    HAEMATOLOGICA, 2014, 99 : 637 - 637
  • [39] Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib
    Mian, Michael
    Pescosta, Norbert
    Badiali, Stefania
    Cappelletto, Paola Cristina
    Marcheselli, Luigi
    Luminari, Stefano
    Patriarca, Francesca
    Zambello, Renato
    Pascarella, Anna
    Tagariello, Giuseppe
    Marabese, Alessandra
    Mondello, Patrizia
    Billio, Atto
    Cortelazzo, Sergio
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (05) : 944 - 947
  • [40] PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB
    Mian, M.
    Pescosta, N.
    Luminari, S.
    Badiali, S.
    Marcheselli, L.
    Patriarca, F.
    Zambello, R.
    Mondello, P.
    Pascarella, A.
    Marabese, A.
    Pitini, V.
    Cortelazzo, S.
    HAEMATOLOGICA, 2014, 99 : 382 - 383
12345